News | Radiation Therapy | April 01, 2016

Pyrexar Announces New Partnership to Bring Hyperthermia Cancer Therapy to Cuba

Distribution network will include Cuba, the West Indies, Panama and Venezuela

Pyrexar Medical, hyperthermia products, Cuba, West Indies, Clinitech Co. Ltd.

April 1, 2016 — Pyrexar Medical announced a new distribution partnership with Clinitech Co. Ltd., bringing Pyrexar’s hyperthermia technologies into Cuba, the West Indies, Panama and Venezuela.

Cancer deaths are high in Cuba at 138 per 100,000, according to World Life Expectancy.com, an organization that tracks death causality throughout the world. Cuba cancer stats rank 31 in the world, slightly lower than the United Kingdom, and several points higher than the United States. According to a study in 2001-2003 by the National Cancer Registry, lung, prostate, throat and colon cancers had high incidence in men, while breast, cervix, lung and colon cancers were the most prevalent in women.

Clinitech will be providing sales and service for the Pyrexar family of superficial, interstitial and deep regional hyperthermia devices. Leading their team is Ross University School of Medicine Oncology Professor Kamal Malaker, M.D., Ph.D., who has successfully used hyperthermia technology in the treatment of cancer. “We are excited to bring this relatively under-explored, under-utilized, well-proven, life-saving technology to the region.” said Wazir Mohammed, Clinitech’s president.

The distribution territory includes: Antigua, Aruba, Bahamas, Barbados, Belize, Bermuda, Bonaire, British Virgin Islands, Cayman Islands, Cuba, Curacao, Dominica, Dominican Republic, Grenada, Guyana, Haiti, Jamaica, Montserrat, Panama, Puerto Rico, Saba, St. Ecstasies, St Kitts & Nevis, St. Lucia, St. Maarten, St. Vincent. Suriname, Trinidad and Tobago, Turks and Caicos, U.S. Virgin Islands (St. Thomas, St. Croix and St John) and Venezuela.

For more information: www.pyrexar.com

Related Content

Immune Inflammatory Levels Linked to Disease-Free Survival in Prostate Cancer
News | Prostate Cancer | November 19, 2018
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...
GE Healthcare Discovery RF Gen 2 system displayed at ASTRO 2018. It is a dedicated computed tomography (CT) scanner for radiation oncology
360 Photos | 360 View Photos | November 07, 2018
This is the GE Healthcare Discovery RF Gen 2 system displayed at the ...
Proton Therapy for Pediatric Brain Tumors Has Favorable Cognitive Outcomes
News | Proton Therapy | November 06, 2018
Proton therapy treatment for pediatric brain tumor patients is associated with better neurocognitive outcomes compared...
Videos | Radiation Oncology | November 06, 2018
Genomics can be used to assess a patient's radiosensitivity, which can be used to increase or decrease the radiation